Quarterly report · Q3

Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥683.0bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥239.1bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥105.5bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥39.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥105.7bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥39.3bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥1.69Tat 2023-12-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.54Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥475.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.22Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥163.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥91.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥53.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥68.7bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.332023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥40.062023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥107.292023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥40.052023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥172m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥2.1bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥127.8bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥13.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥407.7bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥92.0bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥147.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥16.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥682.8bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥121.9bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 653
ItemContextValueUnit
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant187322000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember747682540
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember747682540
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant747682540
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant747682540
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2979300
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember7445442
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember744544200
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember159040
Number of shares issued shares voting rightsCurrentQuarterInstant747682540
Number of voting rights issued shares voting rightsCurrentQuarterInstant7445442
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2979300
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2979300
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.004
Number of shares held in own name treasury shares etcCurrentQuarterInstant2979300
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant2979300
Shareholding ratio treasury shares etcCurrentQuarterInstant0.004
Cash and cash equivalents IFRSPrior1YearInstant187322000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant163633000000JPY
Trade and other receivables ca IFRSPrior1YearInstant150635000000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant178156000000JPY
Other financial assets ca IFRSPrior1YearInstant106000000JPY
Other financial assets ca IFRSCurrentQuarterInstant17750000000JPY
Inventories ca IFRSPrior1YearInstant249618000000JPY
Inventories ca IFRSCurrentQuarterInstant272500000000JPY
Income taxes receivable ca IFRSPrior1YearInstant2920000000JPY
Income taxes receivable ca IFRSCurrentQuarterInstant3669000000JPY
Other current assets ca IFRSPrior1YearInstant20793000000JPY
Other current assets ca IFRSCurrentQuarterInstant33301000000JPY
Current assets IFRSPrior1YearInstant611396000000JPY
Current assets IFRSCurrentQuarterInstant669012000000JPY
Property plant and equipment IFRSPrior1YearInstant370869000000JPY
Property plant and equipment IFRSCurrentQuarterInstant389536000000JPY
Goodwill and intangible assets IFRSPrior1YearInstant538210000000JPY
Goodwill and intangible assets IFRSCurrentQuarterInstant558814000000JPY
Investments accounted for using equity method IFRSPrior1YearInstant3680000000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant1992000000JPY
Other financial assets nca IFRSPrior1YearInstant34421000000JPY
Other financial assets nca IFRSCurrentQuarterInstant27394000000JPY
Deferred tax assets IFRSPrior1YearInstant20458000000JPY
Deferred tax assets IFRSCurrentQuarterInstant21776000000JPY
Other non current assets nca IFRSPrior1YearInstant23187000000JPY
Other non current assets nca IFRSCurrentQuarterInstant23139000000JPY
Non current assets IFRSPrior1YearInstant990829000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass